Consensus Bio-Rad Laboratories, Inc.

Stocks

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 01:14:17 15/10/2026 am IST			5-day change	1st Jan Change
361.48 ^USD	-0.62%		-1.48%	+19.64%

24/09	Bio-Rad Laboratories, Inc. Presents at Bernstein Insights: Healthcare Leaders and Disruptors ? 3rd Annual Healthcare Forum, Sep-24-2026 08:50 AM
10/09	Bio-Rad Laboratories, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03:45 PM

Evolution of the Average Target: Bio-Rad Laboratories, Inc.

Evolution of the Target Price: Bio-Rad Laboratories, Inc.

Changes in Analyst Recommendations: Bio-Rad Laboratories, Inc.

16e32d5f679d23782e5278f.Nrs87Ns_C_ngcHtEy13s4EAM8yR_KAhChf1fmkOasBc.WPNfwb1eaZ-INg4O_zyatS5UoR0TSnwz45MQzArc2SFmwn68oVN4i5IBEA~67888a3e8997864e237fe70cfa5d59b4

Analysts' recommendations: Bio-Rad Laboratories, Inc.

07/08	RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating	MT
05/08	RBC Adjusts Price Target on Bio-Rad Laboratories to $370 From $320, Maintains Outperform Rating	MT
15/05	Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says	MT
07/04	Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375	MT
13/02	UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating	MT
30/25/30	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
03/25/03	RBC Raises Price Target on Bio-Rad Laboratories to $437 From $409, Keeps Outperform Rating	MT
01/25/01	UBS Adjusts Price Target on Bio-Rad Laboratories to $325 From $310, Maintains Buy Rating	MT
01/25/01	RBC Raises Price Target on Bio-Rad Laboratories to $409 From $387, Keeps Outperform Rating	MT
01/25/01	RBC Raises Price Target on Bio-Rad Laboratories to $387 From $381, Keeps Outperform Rating	MT
02/25/02	UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating	MT
02/25/02	RBC Cuts Price Target on Bio-Rad Laboratories to $392 From $409, Keeps Outperform Rating	MT
08/25/08	RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating	MT
14/25/14	UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating	MT
14/25/14	RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating	MT
04/25/04	RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating	MT
09/24/09	RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating	MT
31/24/31	UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating	MT
01/24/01	Citigroup Upgrades Bio-Rad Laboratories to Buy From Neutral, Adjusts Price Target to $400 From $350	MT
13/24/13	RBC Raises Price Target on Bio-Rad Laboratories to $446 From $401, Keeps Outperform Rating	MT
28/24/28	Wells Fargo Initiates Bio-Rad Laboratories at Equalweight With $340 Price Target	MT
02/24/02	Citigroup Adjusts Price Target on Bio-Rad Laboratories to $350 From $300	MT
02/24/02	UBS Adjusts Price Target on Bio-Rad Laboratories to $400 From $385, Maintains Buy Rating	MT
02/24/02	RBC Trims Price Target on Bio-Rad Laboratories to $401 From $402, Keeps Outperform Rating	MT
24/24/24	RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
BIO-RAD LABORATORIES, INC.	-	-9.73%
ABBOTT LABORATORIES		+17.64%
MEDTRONIC PLC		+12.25%
STRYKER CORPORATION		+28.34%
ESSILORLUXOTTICA		+53.08%
CENCORA, INC.		+12.13%
HOYA CORPORATION		+19.3%
BECTON, DICKINSON AND COMPANY		+3.58%
IDEXX LABORATORIES, INC.		+34.79%
DEXCOM, INC.		+13.4%
Average		+18.48%
Weighted average by Cap.		+21.08%